Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Naturland Holding ZrtBUD:NATURLAND 61 Cash-to-Debt is 1.98 as of Jun. 2025, which is 31% below its 10-year median of 2.86. GuruFocus rates BUD:NATURLAND with a GF Score™ of 61/100 and a GF Value™ of Ft2,908.46 (Fairly Valued). The stock has 5 warning signs investors should review. Among 983 Drug Manufacturers companies, Naturland Holding Zrt ranks better than 59.72% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Naturland Holding Zrt's cash to debt ratio for the quarter that ended in Jun. 2025 was 1.98.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Naturland Holding Zrtcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2025.
The historical rank and industry rank for Naturland Holding Zrt's Cash-to-Debt or its related term are showing as below:
BUD:NATURLAND'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.84 Med: 2.86 Max: No Debt
Current: 1.98
During the past 5 years, Naturland Holding Zrt's highest Cash to Debt Ratio was No Debt. The lowest was 0.84. And the median was 2.86.
BUD:NATURLAND's Cash-to-Debt is ranked better than 59.72% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs BUD:NATURLAND: 1.98
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Naturland Holding Zrt Cash-to-Debt Related Terms
Naturland Holding Zrt Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Naturland Holding Zrt's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BUD:NATURLAND vs ZTS, UTHR, VTRS: Cash-to-Debt Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturland Holding Zrt Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Naturland Holding Zrt's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naturland Holding Zrt (BUD:NATURLAND) has a Cash-to-Debt of 1.98 as of Jun. 2025. This is 31% below median its historical median of 2.86. Over the past decade, Naturland Holding Zrt's Cash-to-Debt has ranged from 0.84 to 10,000.00. According to the industry distribution chart, Naturland Holding Zrt ranks #396 out of 983 companies in the Drug Manufacturers industry, placing it in the top 40.3%.
Is Naturland Holding Zrt's Cash-to-Debt too high?
Naturland Holding Zrt's current Cash-to-Debt of 1.98 is 31% below median its 10-year median of 2.86. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Naturland Holding Zrt's value of 1.98 is 102% above this industry median. Based on the distribution chart, Naturland Holding Zrt ranks #396 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Naturland Holding Zrt ranks #396 out of 983 companies for Cash-to-Debt. This puts Naturland Holding Zrt in the upper half of its industry. The industry median Cash-to-Debt is 0.98. Naturland Holding Zrt's value of 1.98 is 102% above this benchmark. Historically, Naturland Holding Zrt's own Cash-to-Debt has ranged from 0.84 to 10,000.00 over the past decade. While the company's 10-year median is 2.86 vs. the industry median of 0.98, Naturland Holding Zrt has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturland Holding Zrt's current Cash-to-Debt of 1.98 is 102% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturland Holding Zrt's current Cash-to-Debt is 1.98, which is 31% below median its own 10-year median of 2.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,908.46, compared to a current price of Ft2,840.00 — trading 2.4% below its estimated fair value. The current Cash-to-Debt is 1.98, which is 31% below median its 10-year median of 2.86 and 102% above the Drug Manufacturers industry median of 0.98. Naturland Holding Zrt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current Cash-to-Debt is 1.98 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued.
The current stock price of Ft2,840.00 is trading 2.4% below its estimated GF Value™ of Ft2,908.46.
GuruFocus considers Naturland Holding Zrt to be Fairly Valued.
Key valuation signals for BUD:NATURLAND:
Cash-to-Debt: 1.98 (31% below median its 10-year median of 2.86)
GF Value™: Ft2,908.46 vs. price of Ft2,840.00 (2.4% below fair value)
Industry Position: 102% above the Drug Manufacturers median (#396 of 983)
No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score
Get the complete analysis for BUD:NATURLAND
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NATURLAND has been successfully added to your 
